Skip to main content

Table 2 Methodology and budget results of BIAs

From: A systematic review of the budget impact analyses for antitumor drugs of lung cancer

First author

Model structure

Perspective

Budget time horizon

Treatment strategy

Cost calculation

Data sources

Sensitivity analysis

Research result

Carlson [31]

Cost calculator

Health plan

1 year

Erlotinib maintenance VS Erlotinib maintenance available

Direct cost + condition-related cost

RCT; Medicare and Medicaid and Drug price database; published literature

One-way

Erlotinib PMPM increase

Farsai [39]

Cost calculator

Hospital

4 years

Docetaxel VS Pemetrexed

Direct cost

Hospital inpatient database

One-way

Annual budget of Pemetrexed in hospital increase

Sumitra [40]

Markov model

CSMBS

5 years

Gefitinib;Erlotinib;Pemetrexed;Docetaxel

Direct cost + condition-related cost

RCT;NICE Public data

One-way

Cost saving of Gefitinib

Preeti [32]

Cost calculator

Private insurance company

1 year

Erlotinib;Pac + Car;Bev + Pac + Car;Pem + Car;Bev + Pem +Car

Direct cost

Hospital medical records; Medicare database

One-way

Erlotinib PMPM increase

Lisa [33]

Cost calculator

Hospital

1 year

Ram + Doc; Bev + Erl; Docetaxel; Erlotinib; Pemetrexed

Direct cost

Public Data;Electronic medical record data

NR

After ramucirumab adding to hospital formulary annual margin increase

Mengyuan [41]

Cost calculator

Medical insurance

5 years

Gefitinib VS chemotherapy

Direct cost

Tumor registration information; Project survey; Drug Market Trend Report

One-way

Budget savings after gefitinib is included in the medical insurance catalog

Sumitra [42]

Cost calculator

Payer

3 years

Crizotinib VS no crizotinib

Direct cost + condition-related cost

Thailand official database; Hospital database

One-way

Crizotinib PMPM increase

Daniel [34]

Monte Carlo model

Payer

1 year

Different dose control of the same drug

Direct cost

RCT/SEER and Medicare data

One-way

Budget savings for pembrolizumab of personalized dosing

Jan [43]

Cost minimization model

Payer

1 year

Pembrolizumab VS Docetaxel or pemetrexed

Direct cost + condition-related cost

RCT; National official data

One-way

Pembrolizumab 2nd-line treatment cost savings

Pedro [44]

NR

Payer

1 year

Cost-sharing, risk-sharing, payment-by-results, discount

Direct cost

RCT; National official data

NR

Budget impact of pembrolizumab in the first-line decreased through risk-sharing

Christopher [35]

Cost calculator

U.S. commercial and Medicare health plans

3 years

Before and after adoption of Neci + GCis

Direct cost + condition-related cost

RCT; U.S. prescription information and clinical guidelines; Public data

One-way

Neci + GCis annual budget increase

Jonathan [36]

Decision model

U.S. commercial health plan

5 years

Constant Uptake VS Increase in Afatinib Uptake

Direct cost + condition-related cost

Public data; Project survey; Published literature

One-way

Afatinib annual budget increase

Xueyan [45]

Cost calculator

Medical insurance

5 years

Icotinib VS chemotherapy

Direct cost

Published literature; Project survey data

One-way

Icotinib annual medical insurance cost budget savings

Jie [46]

Cost calculator

Medical insurance

3 years

With and without afatinib in the Chinese national reimbursement system

Direct cost

Published literature; Clinical expert opinion

One-way

Afatinib annual medical insurance budget expenditure decreases

  1. CSMBS Civil Servant Medical Benefit Scheme, Pac paclitaxel, Car carboplatin, Bev bevacizumab, Pem pemetrexed, Ram ramucirumab, Doc Docetaxel, Neci necitumumab, GCis gemcitabine and cisplatin, NR no report